Dovitinib Trial
Status: Start-Up Phase
An exploratory multinational Phase 1/2 trial, led by The Hospital for Sick Children (SickKids) and Children’s Cancer Institute, evaluating dovitinib in combination with standard of care.
-
Osteosarcoma
-
Seamless Phase ½ biomarker-driven enrollment.
-
Define safe dosing for dovitinib, both alone and in combination with chemotherapy, assess drug efficacy, and evaluate biomarkers.
-
~40 children across multiple cancer types and centers around the world.
-
Daniel Morgenstern, MD, PhD
Staff Physician, Haematology/Oncology at The Hospital for Sick Children (Sickkids)
David Ziegler, MBBS, BSc (Med), MD/PhD, FRACP
Group Leader, Clinical Research Fellow & Haematology/Oncology at Children’s Cancer Insti!u!e